Patents by Inventor David J. Vocadlo

David J. Vocadlo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF
    Publication number: 20230348387
    Abstract: The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 2, 2023
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Jianyu SUN, David J. VOCADLO, Yuanxi ZHOU, Yongbao ZHU
  • INHIBITORS OF PROTEIN FUCOSYLATION AND USES THEREOF
    Publication number: 20230331649
    Abstract: The present invention relates to inhibitors of protein fucosylation. More specifically, the present invention relates to carbacyclic compounds of Formula (I) useful as inhibitors of protein fucosylation, or for treating a cancer, an autoimmune disease, an infectious disease, an inflammatory disease, or sickle cell disease.
    Type: Application
    Filed: June 3, 2021
    Publication date: October 19, 2023
    Inventors: David J. VOCADLO, Robert BRITTON, Yang WANG, Venkata Narasimharao THOTA, Anthony FERS-LIDOU
  • NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF
    Publication number: 20230174486
    Abstract: The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Application
    Filed: May 6, 2021
    Publication date: June 8, 2023
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Jianyu SUN, David J. VOCADLO, Yuanxi ZHOU, Yongbao ZHU
  • Bis-acetal-based substrates for imaging exo-glycosidase activity
    Patent number: 11396522
    Abstract: The invention provides fluorescence-quenched substrates of exo-glycosidase enzymes. The invention also provides methods for imaging exo-glycosidase enzymes activity within cells.
    Type: Grant
    Filed: June 12, 2018
    Date of Patent: July 26, 2022
    Assignee: ALECTOS THERAPEUTICS INC.
    Inventors: David J. Vocadlo, Samy Cecioni, Roger Ashmus
  • NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF
    Publication number: 20220213058
    Abstract: The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Application
    Filed: May 7, 2020
    Publication date: July 7, 2022
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Jianyu SUN, David J. VOCADLO, Yuanxi ZHOU, Yongbao ZHU
  • BIS-ACETAL-BASED SUBSTRATES FOR IMAGING EXO-GLYCOSIDASE ACTIVITY
    Publication number: 20200207800
    Abstract: The invention provides fluorescence-quenched substrates of exo-glycosidase enzymes. The invention also provides methods for imaging exo-glycosidase enzymes activity within cells.
    Type: Application
    Filed: June 12, 2018
    Publication date: July 2, 2020
    Inventors: David J. VOCADLO, Samy CECIONI
  • Glucocerebrosidase modulators and uses thereof
    Patent number: 10081601
    Abstract: The invention provides compounds for modulating glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: September 25, 2018
    Assignee: Alectos Therapeutics Inc.
    Inventors: Ramesh Kaul, Ernest J. McEachern, Jianyu Sun, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu
  • GLUCOCEREBROSIDASE MODULATORS AND USES THEREOF
    Publication number: 20180009761
    Abstract: The invention provides compounds for modulating glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Application
    Filed: September 21, 2017
    Publication date: January 11, 2018
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Jianyu SUN, David J. VOCADLO, Yuanxi ZHOU, Yongbao ZHU
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9815861
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: November 14, 2017
    Assignees: Alectos Therapeutics, Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, Changwei Mu, Harold G. Selnick, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou, Yongbao Zhu
  • Glycosidase inhibitors and uses thereof
    Patent number: 9809537
    Abstract: The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: November 7, 2017
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ernest J. McEachern, Jianyu Sun, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu, Harold G. Selnick
  • Glucocerebrosidase modulators and uses thereof
    Patent number: 9796680
    Abstract: The invention provides isofogamine analogs of structural formula (I) below that modulate and stabilize glucocerebrosidases and enhance their enzymatic activity in vivo. Such compounds, prodrugs and compositions thereof are useful in treating synucleinopathy, lysosomal storage disease and relevant neurodegenerative disease.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: October 24, 2017
    Assignee: Alectos Therapeutics Inc.
    Inventors: Ramesh Kaul, Ernest J. McEachern, Jianyu Sun, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9718854
    Abstract: The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to over-expression of O-GlcNAcase or accumulation of O-GlcNac.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: August 1, 2017
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Kun Liu, Harold G. Selnick, Zhongyong Wei, Changwei Mu, Yaode Wang, Xiaona Wang
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9701693
    Abstract: The invention provides compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: June 27, 2012
    Date of Patent: July 11, 2017
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Tong-Shuang Li, Ernest J. Mceachern, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu, Harold G. Selnick
  • Glycosidase inhibitors and uses thereof
    Patent number: 9695197
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: July 4, 2017
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Qun Dang, Harold G. Selnick
  • Glycosidase inhibitors and uses thereof
    Patent number: 9670195
    Abstract: The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: June 6, 2017
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ernest J. McEachern, Jianyu Sun, David J. Vocadlo, Yuanxi Zhou, Harold G. Selnick
  • GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20170107180
    Abstract: The invention provides compounds for inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: December 19, 2016
    Publication date: April 20, 2017
    Inventors: Ernest J. MCEACHERN, David J. VOCADLO, Yuanxi ZHOU, Harold G. SELNICK
  • GLUCOCEREBROSIDASE MODULATORS AND USES THEREOF
    Publication number: 20170029379
    Abstract: The invention provides isofogamine analogs of structural formula (I) below that modulate and stabilize glucocerebrosidases and enhance their enzymatic activity in vivo. Such compounds, prodrugs and compositions thereof are useful in treating synucleinopathy, lysosomal storage disease and relevant neurodegenerative disease.
    Type: Application
    Filed: December 22, 2014
    Publication date: February 2, 2017
    Applicant: Alectos Therapeutics Inc.
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Jianyu SUN, David J. VOCADLO, Yuanxi ZHOU, Yongbao ZHU
  • Glycosidase inhibitors and uses thereof
    Patent number: 9522883
    Abstract: The invention provides compounds of Formula (I) for inhibiting gh cosidases, prodrugs of the compounds, and pharmaceutical compositions comprising the compounds or prodrugs of the compounds. The invention also provides method of treating diseases and disorders related to deficiency or over-expression of O-gh coprotein 2-acetamido-2-deoxy-?-D-glucopyranosidase (O-GlcNAcase), accumulation or deficiency of 2-acetamido-2-deoxy-?-D-glucopyranoside (O-GlcNAc).
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: December 20, 2016
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Harold G. Selnick
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20160096858
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: December 11, 2015
    Publication date: April 7, 2016
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Changwei MU, Harold G. SELNICK, David J. VOCADLO, Yaode WANG, Zhongyong WEI, Yuanxi ZHOU, Yongbao ZHU
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9243020
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: January 26, 2016
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, Harold G. Selnick, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu